Artelo Biosciences, Inc.  announced the completion of enrollment of the first three cohorts in the Cancer Appetite Recovery Study (CAReS) and the initiation of a fourth cohort expected to complete the first stage of the Phase 1b clinical trial of ART27.13. The CAReS Phase 1b stage focuses on the safety of ascending doses with the objective of identifying the optimal dose for the randomized Phase 2a portion of the study, in which additional safety and activity will be evaluated. The mild to moderate adverse events observed in CAReS that have been attributed to ART27.13 required no dose reductions or terminations and many of the adverse events required no medical intervention at all.

Given the encouraging safety profile and dose-response trend to date, with the goal of maximizing potential utility of ART27.13, Artelo has elected to open enrollment for six patients at a 650 microgram dose per the option in the approved study protocol.